Summary of Viatris 2025 Conference Call Company Overview - **Company**: Viatris (NasdaqGS: VTRS) - **Event**: Jeffries London Healthcare Conference - **Date**: November 18, 2025 Key Points Industry and Company Progress - **2025 Overview**: The year has been characterized by both challenges and significant progress, including strong commercial execution across multiple geographies [2][4] - **Pipeline Success**: Five out of six phase three studies were positive, with launches expected in 2026 and beyond [2][4] - **Capital Return**: Approximately $500 million in share buybacks completed, with over $1 billion anticipated in total capital return to shareholders for 2025 [3][4] Financial Strategy - **Cost Review**: An enterprise-wide strategic review is underway to identify cost savings and ensure the right organizational structure post-merger [4][6] - **Cost Savings**: Expected meaningful savings from the review, with a majority falling to the bottom line and a portion reinvested for growth [10][7] Regulatory and Operational Updates - **FDA Inspection**: Product reinspection by the FDA is anticipated in the first half of 2026, with over 90% of remediation completed [11][12] - **Manufacturing Strategy**: Efforts are being made to qualify other plants and find third-party vendors to ensure product supply regardless of inspection timing [12] Business Development and Capital Allocation - **Balanced Approach**: The capital allocation strategy emphasizes a balance between dividends, share buybacks, and investment in growth assets [13][14] - **Acquisition Focus**: Interest in in-market, high-margin revenue assets, with recent acquisitions in Japan to enhance the portfolio [14][16] Pipeline Highlights - **Upcoming Products**: Excitement around fast-acting meloxicam and Xulane low-dose patch, with launches expected in 2026 [18][19] - **Sotagliflozin**: Currently being registered globally, with strong enthusiasm noted for its potential [19][20] - **Market Opportunity**: The acute pain market in the U.S. is approximately 80 million cases, with a significant portion currently treated with opioids [26][27] Competitive Landscape - **Differentiation**: Fast-acting meloxicam is positioned as a unique offering with a significant opioid-sparing effect, differentiating it from competitors [20][26] - **Presbyopia Market**: Viatris is optimistic about its asset for Presbyopia, highlighting a favorable safety profile compared to competitors [34][35] Revenue Projections - **New Product Revenue**: Anticipated new product revenue for 2026 is projected between $450 million and $550 million, driven by recent approvals and upcoming launches [37][40] - **Overall Growth**: 2026 is expected to be a strong year for revenue growth, supported by both new product launches and a stable base business [42] Conclusion - **Outlook**: Viatris is preparing for a period of sustained growth, with a focus on leveraging its diverse portfolio and geographic presence to capitalize on upcoming opportunities in 2026 and beyond [4][42]